Interaction Checker
Do Not Coadminister
Nirmatrelvir/ritonavir (5 days)
Carbamazepine
Quality of Evidence: Low
Summary:
Coadministration is contraindicated as it may lead to a loss of virological response and possible resistance. Coadministration of carbamazepine (300 mg twice daily for 16 doses) and nirmatrelvir/ritonavir (300/100 mg twice daily for 16 doses) decreased nirmatrelvir Cmax and AUC by 43% and 55%. In addition, inhibition of CYP3A4 by ritonavir may increase concentrations of carbamazepine as it is metabolised by CYP3A4 and UGT2B7. Use an alternative COVID-19 treatment.
Description:
View all available interactions with Nirmatrelvir/ritonavir (5 days) by clicking here.
Copyright © 2025 The University of Liverpool. All rights reserved.